Bariatric Surgery Beats GLP-1s for Cardiovascular Benefit in T2D & Obesity | Meta-Analysis

For individuals managing type 2 diabetes and obesity, a new analysis suggests that bariatric surgery may offer a more substantial long-term benefit for heart health than medications like GLP-1 receptor agonists. The findings, published in Obesity Surgery, indicate a 52% relative risk reduction in major adverse cardiovascular events (MACE) and all-cause mortality for those who underwent metabolic and bariatric surgery (MBS) compared to those treated with GLP-1 RAs.

Understanding the Study and its Scope

The meta-analysis, led by Joshua Chadwick and colleagues from the Indian Council of Medical Research, examined data from 11 studies encompassing nearly 20,000 patients. These studies included randomized controlled trials, propensity score-matched cohorts, and nationwide matched cohorts, drawing participants from the United States, China, Italy, Sweden, Israel, Australia, and Taiwan. The most common surgical procedures included Roux-en-Y gastric bypass and sleeve gastrectomy, while the most frequently prescribed GLP-1 drugs were semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity). Cardiovascular Business provides further details on the study’s scope.

GLP-1s and Bariatric Surgery: A Closer Look

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications initially developed to treat type 2 diabetes. They work by mimicking the effects of the naturally occurring GLP-1 hormone, which helps regulate blood sugar levels, promotes insulin release, and can also lead to weight loss. They’ve gained significant attention recently, not only for diabetes management but also for their potential as weight-loss drugs.

Bariatric surgery, also known as weight-loss surgery, encompasses a variety of procedures that alter the digestive system to limit food intake and/or absorption. These procedures are typically reserved for individuals with severe obesity (a body mass index of 40 or higher, or a BMI of 35 or higher with obesity-related health problems) who have not achieved sufficient weight loss through other methods. The National Center for Biotechnology Information details the use of GLP-1 analogues as adjunct therapies to bariatric surgery.

Interpreting the Risk Reduction

The 52% relative risk reduction observed in the meta-analysis is a significant finding. Though, it’s crucial to understand what this means in practical terms. Relative risk reduction indicates the percentage decrease in risk for the group undergoing bariatric surgery compared to the group on GLP-1 RAs. It doesn’t directly translate to the absolute risk of experiencing a cardiovascular event or death. The absolute risk would depend on the baseline risk of these events in the study populations, which wasn’t explicitly stated in the available summaries.

Nuances and Limitations of the Research

The researchers acknowledge that while both MBS and GLP-1 RAs are effective for improving metabolic health and reducing cardiovascular risk, their risk-benefit profiles differ. Direct comparative evidence on long-term outcomes like MACE and all-cause mortality has been limited until now. The study’s strength lies in its comprehensive analysis of multiple studies, including both randomized controlled trials (considered the gold standard in research) and observational studies.

However, it’s vital to note the inherent limitations of meta-analyses. The quality of the included studies can vary, and potential biases in individual studies can influence the overall results. The researchers addressed this by conducting a sensitivity analysis, using a “leave-one-out” approach to confirm the robustness of their findings. This involves systematically removing each study from the analysis to see if the overall results remain consistent.

What This Means for Patients

These findings do not suggest that GLP-1 medications are ineffective. They remain a valuable tool for managing type 2 diabetes and obesity. However, for individuals who are eligible for and considering bariatric surgery, this research provides further evidence that it may offer a more substantial and lasting benefit for cardiovascular health.

It’s essential to emphasize that bariatric surgery is a major procedure with potential risks and complications. It requires careful evaluation, patient selection, and long-term follow-up. The decision to undergo bariatric surgery should be made in consultation with a qualified healthcare team, including a surgeon, endocrinologist, and registered dietitian.

The Role of Adjunct Therapies

Interestingly, research also explores the potential benefits of combining GLP-1 analogues with bariatric surgery. As noted in the Langenbecks Arch Surg study, some patients may not experience adequate weight loss or may regain weight after surgery, leading to a return of obesity-related health problems. In these cases, GLP-1 analogues can be used as adjunct therapies, either before or after surgery, to help optimize weight loss and metabolic outcomes.

Future Directions and Ongoing Research

The findings from this meta-analysis are likely to stimulate further research in this area. Ongoing clinical trials are investigating the long-term effects of both bariatric surgery and GLP-1 medications on cardiovascular outcomes. Researchers are also exploring ways to identify which patients are most likely to benefit from each treatment approach.

Further investigation is needed to understand the mechanisms by which bariatric surgery provides superior cardiovascular protection. This could involve studying the effects of surgery on gut hormones, inflammation, and other metabolic pathways.

What comes next: The medical community will be closely monitoring the results of ongoing trials and updating clinical guidelines as new evidence emerges. Patients are encouraged to discuss their individual risk factors and treatment options with their healthcare providers to make informed decisions about their care.